Mayo Clinic trial explores low-dose radiation against Parkinson's brain inflammation
Mayo Clinic researchers have launched the first clinical trial testing low-dose radiation as an anti-inflammatory strategy in early Parkinson's disease. Unlike cancer treatment, the study uses much lower targeted doses with the aim of modifying an underlying disease process rather than only easing symptoms. The trial focuses on inflammation in brain regions affected by Parkinson's.
The Mayo study enrolls people in the early phase of Parkinson's, a progressive nervous-system movement disorder marked by slowness, tremor, rigidity, and balance or posture trouble. Patients may also face cognitive, mood, fatigue, and anxiety symptoms. The condition involves loss of dopamine-making neurons and abnormal protein deposits, and no cure exists; current care mainly controls symptoms through medication or selected procedures.
Unlike oncology radiation, which uses stronger doses to injure tumors, this protocol aims at small brain regions tied to Parkinson's. Imaging guides targeting, blood markers and symptom assessments are collected, and participants receive five daily sessions of roughly 10–15 minutes. Researchers will track inflammatory markers and protein buildup.
Because the trial is small and early-stage, its main societal effect may be to shape how patients, families, and clinicians think about neuroinflammation as a treatable target. If later results show benefit, low-dose radiation could become an additional option alongside symptom-focused care, though access, cost, and long-term safety would need study. It may also stimulate broader research into inflammation across neurodegenerative diseases, but no patient-level impact is established yet.